Werewolf Therapeutics advances a pipeline of INDUKINE™ molecules, a novel class of systemically delivered, conditionally activated proinflammatory immune modulators. The company uses its proprietary PREDATOR™ protein engineering platform to create therapeutics that are inactive in circulation and selectively activated within the tumor microenvironment. Its lead candidates, WTX-124 (IL-2) and WTX-330 (IL-12), aim to deliver full cytokine potency in tumors while minimizing off-target toxicities that limit systemic cytokine therapies. Preclinical studies reportedly showed anti-tumor activity and favorable pharmacokinetic and safety profiles. Werewolf plans to advance its lead programs into Phase 1 clinical proof-of-concept studies and to progress additional programs to IND-readiness using proceeds from the financing. The company is building its team for clinical development, including recent appointments of Randi Isaacs as Chief Medical Officer and Ellen Lubman as Chief Business Officer. Werewolf Therapeutics is a Cambridge, Mass.-based oncology biotherapeutics company advancing a pipeline of cancer treatments built on its PREDATOR™ protein engineering platform. The platform produces biologics that can be systemically delivered in an inactivated format and are selectively activated within the tumor microenvironment to unleash cytokines and immune stimulatory antibodies. Initial drug development efforts focus on INDUKINESTM, conditionally activated cytokines designed to safely and effectively deliver potent antitumor immunity. The company is led by President and CEO Daniel J. Hicklin, Ph.D., with co-founder Luke Evnin, Ph.D. serving as Chairman. Werewolf plans to use the financing to invest in research, talent acquisition and to advance its platform and therapeutic programs toward early clinical development. The company completed a $56M Series A financing to support these efforts.

Total raised

$128M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2021